Summary of pA2, slope, and pKB values for the competitive antagonists in dog subcutaneous resistance arteries
| Antagonist | pA2 | Slope ± S.E. | pKB ± S.E. (n) | ||||
|---|---|---|---|---|---|---|---|
| Agonist Concentration | Mean pKB | ||||||
| 1 nM | 10 nM | 0.1 μM | 1 μM | ||||
| Prazosin | 8.36 | −0.8 ± 0.18 | 8.58 ± 0.5 (4) | 8.45 ± 0.27 (5) | 8.3 ± 0.29 (4) | 8.45 ± 0.18 (13) | |
| BMY 7378 | —2-a | — | No shift (2) | No shift (4) | 6.51 ± 0.47 (4) | — | |
| HV 723 | 8.81 | −0.97 ± 0.24 | 8.72 ± 0.33 (4) | 8.86 ± 0.28 (9) | 8.70 ± 0.3 (7) | 8.78 ± 0.17 (20) | |
| WB4101 | 8.42 | −1.17 ± 0.21 | 8.07 ± 0.5 (4) | 8.82 ± 0.19 (6) | 8.47 ± 0.05 (5) | 8.50 ± 0.16 (15) | |
| 5-Methyl-urapidil | 8.08 | −0.79 ± 0.14 | 7.96 ± 0.18 (7) | 8.01 ± 0.18 (9) | 7.57 ± 0.2 (9) | 7.84 ± 0.11 (25) | |
↵2-a —, value not calculated.